INFLIXIMAB-DYYB | B125544 | CELLTRION INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Apr. 5, 2028 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12303483(formulation) · relevance 55/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Approved Biosimilars
32 AI-discovered patents, sorted by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Mass. | 2017-05-31 | Terminated 2018-07-31 | — | |
| D. Mass. | 2015-03-06 | Terminated 2018-03-15 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.